Mocravimod - Kyorin Pharmaceutical/Novartis

Drug Profile

Mocravimod - Kyorin Pharmaceutical/Novartis

Alternative Names: KRP-203

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Novartis
  • Class Anti-inflammatories; Propylene glycols
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Inflammatory bowel diseases; Transplant rejection
  • Discontinued Cutaneous lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 29 Jan 2018 Chemical structure information added
  • 15 Dec 2016 Biomarkers information updated
  • 16 Nov 2015 Discontinued - Phase-II for Inflammatory bowel disease in Japan (PO) (Kyorin Pipeline, November 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top